{"title":"更正“焦替尼加卡培他滨随机对照试验的汇总分析和对HER2阳性复发或转移性癌症一线选择的反思”","authors":"","doi":"10.1002/cai2.69","DOIUrl":null,"url":null,"abstract":"<p>Guan X, Ma F, Xu B. Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer. Cancer Innovation.2022;1-5.</p><p>In the funding information, the Grant/Award Number of National Nature Science Foundation of China was incorrect. The Grant/Award Number should be “82103634”.</p><p>We apologize for this error.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 4","pages":"318"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.69","citationCount":"0","resultStr":"{\"title\":\"Correction to “Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer”\",\"authors\":\"\",\"doi\":\"10.1002/cai2.69\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Guan X, Ma F, Xu B. Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer. Cancer Innovation.2022;1-5.</p><p>In the funding information, the Grant/Award Number of National Nature Science Foundation of China was incorrect. The Grant/Award Number should be “82103634”.</p><p>We apologize for this error.</p>\",\"PeriodicalId\":100212,\"journal\":{\"name\":\"Cancer Innovation\",\"volume\":\"2 4\",\"pages\":\"318\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.69\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Innovation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cai2.69\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Innovation","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cai2.69","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Correction to “Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer”
Guan X, Ma F, Xu B. Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer. Cancer Innovation.2022;1-5.
In the funding information, the Grant/Award Number of National Nature Science Foundation of China was incorrect. The Grant/Award Number should be “82103634”.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
